Ver­tex wins third CF ap­proval in Eu­rope; ERS Ge­nomics grants Defini­GEN ac­cess to CRISPR/Cas9 tech

→ Ver­tex $VRTX has scored its third cys­tic fi­bro­sis treat­ment ap­proval, with the Eu­ro­pean Com­mis­sion giv­ing Symke­vi (teza­caftor/iva­caftor) in com­bi­na­tion with Ka­ly­de­co (iva­caftor)

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER